Direct answer: At proper doses, masseter Botox does not sag your face. Botulinum toxin only relaxes the chewing muscle and reduces its volume — it has no effect on the ligaments, bone, or skin supporting the face. The ‘sagging’ phenomenon occurs when the masseter atrophies too aggressively at the same time age-related cheek fat loss is underway: the lower-jaw padding thins, the cheek fat pad loses support below and visually descends, creating hollows and looseness. High-risk patients (over 30, thin cheeks) can avoid it entirely with split low-dose treatments and a target that stops short of an extremely slim jaw.
‘I heard masseter Botox eventually makes your face sag and deepens the nasolabial folds?’ — this is the most common rumor that scares people away from jaw Botox. Behind the rumor lies a real mechanism, but it only occurs under specific conditions and is entirely preventable. This guide explains the true cause, who is at risk, and the prevention strategy.
Why is masseter Botox linked to ‘sagging’?
- Botox only reaches the masseter: botulinum toxin blocks the nerve signals that contract the muscle, letting it shrink through disuse. It does not act on skin, ligaments, or bone — the facial support structure remains untouched
- The masseter is the jawline’s cushion: a developed masseter provides volume support along the jaw angle. If this cushion shrinks too fast or too much, the cheek fat pad loses the platform beneath it and visually collapses inward and downward
- The real sagging formula: excessive masseter atrophy (usually from overdosing or pursuing an extreme V-face) + age-related cheek fat loss + declining skin elasticity. It takes all three together to produce visible hollowing. Remove any one and the result is usually just a smaller-looking face
- Why folds can look deeper: after slimming, some patients notice the mid-cheek descent becomes more visible when smiling. This is a volume redistribution effect — correctable with a little mid-face filler or collagen stimulation — not actual skin laxity
Who needs to be careful?
- Over 30: cheek fat is naturally declining; simultaneous major masseter reduction raises hollowing risk. Target a ‘softened jawline’ rather than an extreme V-face
- Naturally thin cheeks: with little fat buffer, masseter volume changes show directly on the contour — doses must be conservative
- ‘One-and-done’ minimalists: requesting a large first dose makes the muscle atrophy far faster than tissue can adapt. Splitting the treatment lets the face keep up with the change
- Existing mild mid-face descent: discuss a combined ‘slimming + mid-face support’ plan rather than simply shrinking the masseter
- Low-risk patients: younger patients with full cheeks and genuinely hypertrophic masseters (night grinding, hard-food chewers) typically see pure improvement with little sagging concern
How to prevent it: split dosing and target setting
- Conservative first dose: the first round softens the jawline with a moderate dose; after observing the facial response for 4-6 weeks, decide whether to add more. Everyone’s ‘golden volume’ differs — approaching it in steps is safer than arriving at once
- Set a stop point: agree with your physician on the target state — a defined but still palpable masseter, never ‘can’t feel the muscle at all’
- Watch the cheeks too: at every follow-up, check cheek hollowing and fold changes alongside the masseter; at the first sign, slow the pace or adjust strategy
- Combine when needed: for visible cheek fat loss, pair with collagen-stimulating treatments or a little mid-face filler to keep upper volume supported — balancing ‘reduce below, support above’
Rappoel’s real jaw-Botox assessment process
- Step 1 — muscle and face analysis: palpating masseter thickness and strength, plus assessing cheek fat and mid-face support, so sagging risk is part of the first evaluation
- Step 2 — goal alignment: showing the difference between natural slimming and extreme slimming, and setting a target matched to your facial proportions rather than maximal reduction
- Step 3 — split injection: conservative symmetric doses for both sides, with photo comparison at the 4-6 week follow-up before any second round
- Step 4 — photo tracking: same-angle photos of the jawline, cheeks, and folds at every visit, giving objective grounds for adjustment
- Step 5 — long-term rhythm: once stable, maintenance runs about every 4-6 months with progressively reduced doses as the muscle shrinks — preventing over-atrophy
The lower bound of jaw Botox is ‘a smaller masseter’; the upper bound is ‘facial harmony’. Staying on that line leaves the sagging rumor irrelevant to you.
Side effects and who should not do it
- Common and temporary: injection-site soreness (1-3 days), chewing weakness (adapts within 1-2 weeks), occasional asymmetric smile (dose distribution issue, resolves in weeks)
- Dose-related risks: over-atrophy of the masseter, cheek hollowing, deeper-appearing folds — all reversible volume effects; the muscle gradually recovers over 3-6 months after stopping
- Not recommended for: pregnancy and breastfeeding, active infection at the injection site, neuromuscular diseases such as myasthenia gravis, allergy to botulinum toxin components
- Special considerations: patients taking aminoglycoside antibiotics should disclose this; those planning major surgery should confirm timing with the physician
Related reading: the rebound science in Does Masseter Botox Rebound; overall injection frequency in Botox Frequency Guide; expression effects in Forehead Botox and Expressions; the complete overview in Seoul Jaw Botox Guide; injection frequency in Botox Frequency Guide.
Frequently Asked Questions
Worried about cheek hollowing from jaw Botox? Rappoel assesses sagging risk at the first visit and uses split dosing for a natural slimming!
📍 77, Seocho-daero, Seocho-gu, Seoul, South Korea
🕐 Mon–Fri 10:00–19:00 · Sat 10:00–17:00
💬 WeChat Main: rappoelkr | WeChat Backup: rappoelkr2 | LINE: rappoelkr
Scan to connect with us
WeChat (Main)
WeChat (Backup)
LINE